GUGGENHIME ANDREW has filed 100 insider transactions across 2 companies since January 2024.
Most recent transaction: a tax payment of 1021 shares of Vaxcyte, Inc. ($PCVX) on March 09, 2026.
Activity breakdown: 0 open-market purchases and 38 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 9, 2026 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | F | Common Stock | 1021 | $59.32 | 166,245.0000 | 136,196,512 | 0.61% | 0.00% |
| Feb. 26, 2026 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | A | Stock Option (right to buy) | 74993 | $0.00 | 74,993.0000 | 136,196,512 | 9999.99% | 0.06% |
| Feb. 26, 2026 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | A | Common Stock | 44864 | $0.00 | 169,173.0000 | 136,196,512 | 36.09% | 0.03% |
| Feb. 28, 2026 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | F | Common Stock | 898 | $61.98 | 168,275.0000 | 136,196,512 | 0.53% | 0.00% |
| March 2, 2026 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | F | Common Stock | 1009 | $61.98 | 167,266.0000 | 136,196,512 | 0.60% | 0.00% |
| Feb. 20, 2026 | Caribou Biosciences, Inc. | $CRBU | GUGGENHIME ANDREW | Director | A | Option to purchase Common Stock | 45000 | $0.00 | 45,000.0000 | 93,468,038 | 9999.99% | 0.05% |
| Jan. 14, 2026 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | G | Common Stock | 61850 | $0.00 | 124,309.0000 | 136,196,512 | 99.02% | 0.05% |
| Jan. 14, 2026 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | G | Common Stock | 61850 | $0.00 | 124,309.0000 | 136,196,512 | 33.22% | 0.05% |
| Sept. 8, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | F | Common Stock | 2890 | $32.41 | 124,309.0000 | 121,997,348 | 2.27% | 0.00% |
| Sept. 2, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | F | Common Stock | 2381 | $31.56 | 128,628.0000 | 121,997,348 | 1.82% | 0.00% |
| Sept. 2, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | F | Common Stock | 1429 | $31.56 | 127,199.0000 | 121,997,348 | 1.11% | 0.00% |
| Sept. 2, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | F | Common Stock | 1270 | $31.56 | 131,009.0000 | 121,997,348 | 0.96% | 0.00% |
| April 7, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 4777 | $0.00 | 121,115.0000 | 121,997,348 | 3.79% | 0.00% |
| April 7, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 4777 | $20.93 | 131,950.0000 | 121,997,348 | 3.76% | 0.00% |
| Feb. 27, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | A | Stock Option (right to buy) | 75991 | $0.00 | 75,991.0000 | 121,997,348 | 9999.99% | 0.06% |
| Feb. 27, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | A | Common Stock | 22761 | $0.00 | 132,252.0000 | 121,997,348 | 20.79% | 0.02% |
| Feb. 28, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | F | Common Stock | 1270 | $73.02 | 130,982.0000 | 121,997,348 | 0.96% | 0.00% |
| March 3, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | F | Common Stock | 3809 | $72.10 | 127,173.0000 | 121,997,348 | 2.91% | 0.00% |
| Feb. 20, 2025 | Caribou Biosciences, Inc. | $CRBU | GUGGENHIME ANDREW | Director | A | Option to purchase Common Stock | 40500 | $0.00 | 40,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 18, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 1818 | $84.58 | 109,491.0000 | 121,997,348 | 1.63% | 0.00% |
| Feb. 18, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 6182 | $83.64 | 111,309.0000 | 121,997,348 | 5.26% | 0.01% |
| Feb. 18, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 8000 | $5.35 | 117,491.0000 | 121,997,348 | 7.31% | 0.01% |
| Feb. 18, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 8000 | $0.00 | 246,827.0000 | 121,997,348 | 3.14% | 0.01% |
| Jan. 21, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 1999 | $87.25 | 110,174.0000 | 121,997,348 | 1.78% | 0.00% |
| Jan. 21, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 683 | $87.70 | 109,491.0000 | 121,997,348 | 0.62% | 0.00% |
| Jan. 21, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 8000 | $0.00 | 254,827.0000 | 121,997,348 | 3.04% | 0.01% |
| Jan. 21, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 8000 | $5.35 | 117,491.0000 | 121,997,348 | 7.31% | 0.01% |
| Jan. 21, 2025 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 5318 | $86.08 | 112,173.0000 | 121,997,348 | 4.53% | 0.00% |
| Dec. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 3157 | $89.31 | 109,771.0000 | 123,693,461 | 2.80% | 0.00% |
| Dec. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 3373 | $88.70 | 112,928.0000 | 123,693,461 | 2.90% | 0.00% |
| Dec. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 1190 | $87.26 | 116,301.0000 | 123,693,461 | 1.01% | 0.00% |
| Dec. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 8000 | $5.35 | 117,491.0000 | 123,693,461 | 7.31% | 0.01% |
| Dec. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 280 | $90.24 | 109,491.0000 | 123,693,461 | 0.26% | 0.00% |
| Dec. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 8000 | $0.00 | 262,827.0000 | 123,693,461 | 2.95% | 0.01% |
| Nov. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 8000 | $5.35 | 117,491.0000 | 123,693,461 | 7.31% | 0.01% |
| Nov. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 6111 | $85.60 | 111,380.0000 | 123,693,461 | 5.20% | 0.00% |
| Nov. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 1757 | $86.49 | 109,623.0000 | 123,693,461 | 1.58% | 0.00% |
| Nov. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 132 | $87.05 | 109,491.0000 | 123,693,461 | 0.12% | 0.00% |
| Nov. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 8000 | $0.00 | 270,827.0000 | 123,693,461 | 2.87% | 0.01% |
| Nov. 7, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | A | Performance Restricted Stock Units | 35661 | $0.00 | 35,661.0000 | 123,693,461 | 9999.99% | 0.03% |
| Nov. 7, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | A | Performance Stock Option (right to buy) | 87481 | $0.00 | 87,481.0000 | 123,693,461 | 9999.99% | 0.07% |
| Oct. 25, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 19108 | $20.93 | 109,491.0000 | 123,693,461 | 21.14% | 0.02% |
| Oct. 25, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 19108 | $0.00 | 125,892.0000 | 123,693,461 | 13.18% | 0.02% |
| Oct. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 5886 | $116.19 | 90,383.0000 | 123,693,461 | 6.11% | 0.00% |
| Oct. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 12000 | $0.00 | 292,827.0000 | 123,693,461 | 3.94% | 0.01% |
| Oct. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 14000 | $0.00 | 278,827.0000 | 123,693,461 | 4.78% | 0.01% |
| Oct. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 8000 | $0.00 | 304,827.0000 | 123,693,461 | 2.56% | 0.01% |
| Oct. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 36114 | $115.26 | 96,269.0000 | 123,693,461 | 27.28% | 0.03% |
| Oct. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 14000 | $5.35 | 132,383.0000 | 123,693,461 | 11.83% | 0.01% |
| Oct. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 12000 | $5.35 | 118,383.0000 | 123,693,461 | 11.28% | 0.01% |
| Oct. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 8000 | $5.35 | 106,383.0000 | 123,693,461 | 8.13% | 0.01% |
| Oct. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 8000 | $5.35 | 98,383.0000 | 123,693,461 | 8.85% | 0.01% |
| Oct. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 8000 | $0.00 | 312,827.0000 | 123,693,461 | 2.49% | 0.01% |
| Sept. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 8000 | $0.00 | 320,827.0000 | 97,157,690 | 2.43% | 0.01% |
| Sept. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 1686 | $116.29 | 91,212.0000 | 97,157,690 | 1.81% | 0.00% |
| Sept. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 5485 | $115.60 | 92,898.0000 | 97,157,690 | 5.58% | 0.01% |
| Sept. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 8000 | $5.35 | 98,383.0000 | 97,157,690 | 8.85% | 0.01% |
| Sept. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 829 | $117.53 | 90,383.0000 | 97,157,690 | 0.91% | 0.00% |
| Sept. 3, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | F | Common Stock | 6337 | $110.15 | 90,383.0000 | 97,157,690 | 6.55% | 0.01% |
| Aug. 19, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 3006 | $79.14 | 96,720.0000 | 97,157,690 | 3.01% | 0.00% |
| Aug. 19, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 8000 | $5.35 | 104,720.0000 | 97,157,690 | 8.27% | 0.01% |
| Aug. 19, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 4994 | $78.25 | 99,726.0000 | 97,157,690 | 4.77% | 0.01% |
| Aug. 19, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 8000 | $0.00 | 328,827.0000 | 97,157,690 | 2.38% | 0.01% |
| July 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 3095 | $80.12 | 101,625.0000 | 97,157,690 | 2.96% | 0.00% |
| July 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 926 | $83.14 | 96,720.0000 | 97,157,690 | 0.95% | 0.00% |
| July 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 1479 | $82.32 | 97,646.0000 | 97,157,690 | 1.49% | 0.00% |
| July 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 2500 | $81.06 | 99,125.0000 | 97,157,690 | 2.46% | 0.00% |
| July 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 8000 | $5.35 | 104,720.0000 | 97,157,690 | 8.27% | 0.01% |
| July 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 8000 | $0.00 | 336,827.0000 | 97,157,690 | 2.32% | 0.01% |
| June 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 8000 | $0.00 | 344,827.0000 | 97,157,690 | 2.27% | 0.01% |
| June 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 348 | $72.56 | 96,720.0000 | 97,157,690 | 0.36% | 0.00% |
| June 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 7652 | $71.89 | 97,068.0000 | 97,157,690 | 7.31% | 0.01% |
| June 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 8000 | $5.35 | 104,720.0000 | 97,157,690 | 8.27% | 0.01% |
| May 20, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 8000 | $5.35 | 103,679.0000 | 97,157,690 | 8.36% | 0.01% |
| May 20, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 4456 | $75.46 | 95,679.0000 | 97,157,690 | 4.45% | 0.00% |
| May 20, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 8000 | $0.00 | 352,827.0000 | 97,157,690 | 2.22% | 0.01% |
| May 20, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 3544 | $74.40 | 100,135.0000 | 97,157,690 | 3.42% | 0.00% |
| April 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 376 | $61.90 | 95,679.0000 | 97,157,690 | 0.39% | 0.00% |
| April 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 8000 | $0.00 | 360,827.0000 | 97,157,690 | 2.17% | 0.01% |
| April 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 8000 | $5.35 | 103,679.0000 | 97,157,690 | 8.36% | 0.01% |
| April 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 7624 | $61.24 | 96,055.0000 | 97,157,690 | 7.35% | 0.01% |
| March 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 7764 | $69.00 | 95,915.0000 | 97,157,690 | 7.49% | 0.01% |
| March 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 8000 | $5.35 | 103,679.0000 | 97,157,690 | 8.36% | 0.01% |
| March 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 8000 | $0.00 | 368,827.0000 | 97,157,690 | 2.12% | 0.01% |
| March 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 236 | $69.64 | 95,679.0000 | 97,157,690 | 0.25% | 0.00% |
| Feb. 29, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | A | Common Stock | 20000 | $0.00 | 99,474.0000 | 97,157,690 | 25.17% | 0.02% |
| March 2, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | F | Common Stock | 3795 | $71.55 | 95,679.0000 | 97,157,690 | 3.82% | 0.00% |
| Feb. 29, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | A | Stock Option (right to buy) | 90000 | $0.00 | 90,000.0000 | 97,157,690 | 9999.99% | 0.09% |
| Feb. 20, 2024 | Caribou Biosciences, Inc. | $CRBU | GUGGENHIME ANDREW | Director | A | Option to purchase Common Stock | 39500 | $0.00 | 39,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 20, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 8000 | $5.35 | 87,474.0000 | 97,157,690 | 10.07% | 0.01% |
| Feb. 20, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 4909 | $74.08 | 82,565.0000 | 97,157,690 | 5.61% | 0.01% |
| Feb. 20, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 2751 | $75.17 | 79,814.0000 | 97,157,690 | 3.33% | 0.00% |
| Feb. 20, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 340 | $75.80 | 79,474.0000 | 97,157,690 | 0.43% | 0.00% |
| Feb. 20, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 8000 | $0.00 | 376,827.0000 | 97,157,690 | 2.08% | 0.01% |
| Jan. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Stock Option (right to buy) | 8000 | $0.00 | 384,827.0000 | 97,157,690 | 2.04% | 0.01% |
| Jan. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 23 | $63.35 | 79,474.0000 | 97,157,690 | 0.03% | 0.00% |
| Jan. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 463 | $61.88 | 79,497.0000 | 97,157,690 | 0.58% | 0.00% |
| Jan. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 3127 | $61.19 | 79,960.0000 | 97,157,690 | 3.76% | 0.00% |
| Jan. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | S | Common Stock | 4387 | $60.28 | 83,087.0000 | 97,157,690 | 5.02% | 0.00% |
| Jan. 18, 2024 | Vaxcyte, Inc. | $PCVX | GUGGENHIME ANDREW | PRESIDENT AND CFO | M | Common Stock | 8000 | $5.35 | 87,474.0000 | 97,157,690 | 10.07% | 0.01% |